Gelnique generic
Gelnique is an overactive bladder treatment drug owned by Allergan. The active ingredient in Gelnique is oxybutynin chloride, and it was first authorized for market use on 27 January, 2009. The drug is available in gel;transdermal dosage forms and holds a total of 3 patents.
When will Gelnique generic be available?
The generic versions of Gelnique might be available after the expiry of the last patent on 26 March, 2031. This release date takes into account the expiration dates of all patents, including possible extensions.
Gelnique uses
Gelnique is used for the treatment of overactive bladder. It works by applying oxybutynin chloride gel to the skin, which helps in treating patients with symptoms of urinary frequency, urgency, or urge incontinence. The gel comes in a single unit dose containing 10% of the active ingredient, oxybutynin chloride.
Gelnique patent expiration
Gelnique holds a total of 3 patents. Most of these patents are related to the unique system and method used for treating overactive bladders and for the administration of the oxybutynin composition. The last patent for Gelnique is set to expire on March 26, 2031, opening the door for the release of Gelnique generics. Below are the details of the patents: